[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:her2-low":3},{"name":4,"total":5,"recruiting":6,"trials":7},"ERBB2 Gene",31,27,[8,16,23,30,36,43,49,56,62,67,73,79,85,91,97,103,109,115,121,126,132,138,144,150,156,162,168,174,180,186,192],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07198724","ERADICATE: A Phase Ib\u002FII Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4\u002F6 Inhibitor and Endocrine-resistant HR+\u002FHER2-low or HER2-ultralow Metastatic Breast Cancer",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:00.873391Z","2026-07-05T05:32:16.660998Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06263543","Sequencing Antibody Drug Conjugates in ER+\u002FHER2 LOW\u002FULTRA LOW MBC",[20],"Phase 2","2026-08-26T02:18:23.582895Z","2026-05-05T02:43:29.578585Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT04144023","A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ",[27],"Phase 1","2026-08-26T02:16:49.565137Z","2026-05-05T02:43:29.361204Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06518837","Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive\u002FHER2 Negative Breast Cancer",[20],"2026-08-26T02:15:24.145250Z","2026-05-05T02:43:28.807707Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT06072612","Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.",[40],"Phase 3","2026-08-26T02:18:29.369233Z","2026-05-05T02:43:28.478069Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT06253494","Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer",[12],"2026-08-26T02:15:54.846520Z","2026-05-05T02:43:28.474793Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":54,"content_modified":55},"NCT06926868","A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)",[53],"Phase 2\u002FPhase 3","2026-08-26T02:16:57.705506Z","2026-05-05T02:43:28.347122Z",{"nct_id":57,"title":58,"phases":59,"status":13,"updated_at":60,"content_modified":61},"NCT06819007","Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)",[40],"2026-08-26T02:18:27.904411Z","2026-05-05T02:43:28.293021Z",{"nct_id":63,"title":64,"phases":65,"status":13,"updated_at":47,"content_modified":66},"NCT04553770","Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer",[20],"2026-05-05T02:43:28.285926Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07078604","A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer",[20],"2026-08-26T02:15:41.377360Z","2026-05-05T02:43:28.163077Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06963905","Saci Nivo Rela for TNBC",[12],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:28.125379Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06340568","A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer",[40],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:27.635834Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06533826","TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd",[20],"2026-08-26T02:17:26.640202Z","2026-05-05T02:43:27.433128Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT06224673","ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer",[20],"2026-08-26T02:18:25.327036Z","2026-05-05T02:43:27.428063Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06806930","Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)",[20],"2026-08-26T02:16:04.914942Z","2026-05-05T02:43:27.108981Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT07069595","PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease",[20],"2026-08-26T02:15:37.042762Z","2026-05-05T02:43:26.906414Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT07112053","A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer",[20],"2026-08-26T02:17:41.695983Z","2026-05-05T02:43:26.708996Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT06414733","HER-2 B Cell Peptide Vaccine",[27],"2026-08-26T02:15:58.452248Z","2026-05-05T02:35:31.723910Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":71,"content_modified":125},"NCT05861895","HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors",[27],"2026-04-29T02:57:57.119787Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT07174336","A Study of Tersolisib (LY4064809\u002FSTX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)",[40],"2026-08-26T02:19:22.562392Z","2026-04-29T02:57:57.088514Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT05795101","TRUDI: TDXD+Durva in HER2+\u002FLow IBC",[20],"2026-08-26T02:18:14.396999Z","2026-05-05T02:43:28.656877Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT04379596","Ph1b\u002F2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)",[20],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:28.509515Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT06364410","Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors",[27],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:28.188138Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT06293898","Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors",[27],"2026-08-26T02:16:23.080181Z","2026-07-24T01:27:14.888332Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT05872295","IKS014 in Advanced Solid Tumors That Express HER2",[27],"2026-08-26T02:19:16.454910Z","2026-07-05T05:32:16.816198Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT06230185","CtDNA Based MRD Testing for NAC Monitoring in TNBC",[],"2026-08-26T02:16:33.772093Z","2026-05-13T02:55:06.427911Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT06927895","Breast Cancer Implementation Science Study With Educational Intervention",[],"2026-08-26T02:18:51.009190Z","2026-05-05T02:43:26.929752Z",{"nct_id":175,"title":176,"phases":177,"status":178,"updated_at":34,"content_modified":179},"NCT07619365","Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer",[20],"NOT_YET_RECRUITING","2026-06-04T01:30:07.902922Z",{"nct_id":181,"title":182,"phases":183,"status":178,"updated_at":184,"content_modified":185},"NCT06251544","TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer",[27],"2026-08-26T02:15:01.639696Z","2026-05-05T02:43:28.485651Z",{"nct_id":187,"title":188,"phases":189,"status":178,"updated_at":190,"content_modified":191},"NCT07465172","GDF-15 and Its Relationship With Treatment-related ADverse Events in Breast Cancer",[],"2026-08-26T02:15:04.877798Z","2026-05-05T02:35:31.607320Z",{"nct_id":193,"title":194,"phases":195,"status":196,"updated_at":197,"content_modified":198},"NCT06157892","A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T02:40:44.217164Z","2026-04-29T02:57:57.142228Z"]